BNET Industries
Market Cap:$145.5M
Last Fiscal Year Sales:$231.7K
- Public
- US
Dow Jones Description
StemCells, Inc. is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. Our aim is to restore or support organ function, improve patients lives and reduce the substantial health care costs associated with these diseases and disorders by identifying and developing stem and progenitor cells as potential therapeutic agents. We currently have two product development programs at the Company: (i) our CNS Program, which is developing applications for our proprietary human neural stem cell and (ii) our Liver Program, which is developing applications for our proprietary human liver engrafting cells. In our CNS Program, we are focused on developing applications for our HuCNS-SC ® product candidate (purified human neural stem cells) for disorders of the central nervous system (CNS). Our HuCNS-SC product candidate is in clinical development for two indications. In January 2009, we completed a six patient Phase I clinical trial to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), two forms of a group of disorders often referred to as Batten disease. We expect to complete data analysis and to report the results of this trial in mid 2009. ...
Number of Employees 55
Contact Information
3155 Porter Dr
Palo Alto, California 94304-1213
(650) 475-3100
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
Recent Events
-
StemCells STEM Posts Q3 Loss of 5c, Tops by 2c
-
StemCells raises $12.5 million through private placement of common stock
-
STEM CELLS Promotes Miodrag Stojkovic to Editor
News & Analysis
Filter by
stem-cell and stemcells inc. - All News and Analysis
U.S. Patent Office Upholds StemCells, Inc.'s Patents in Reexamination Decisions
PALO ALTO, Calif. -- StemCells, Inc. (NASDAQ:STEM) announced today that the U.S. Patent and Trademark Office PTO has upheld two of the Company's neural stem cell patents, with only minor amendments, thereby rejecting the arguments raised by Neuralstem, Inc. in its reexamination petitions of last year. The upheld patents,...
Patent Office Ruling in Favor of Neuralstem Leads to Stay of Stemcells Inc. Lawsuit.
ROCKVILLE, Maryland, June 26 /PRNewswire/ -- Neuralstem Inc. (OTC Bulletin Board: NRLS) said today that StemCells Inc. (Nasdaq: STEM) has consented to a stay of the lawsuit it filed against Neuralstem in August 2006. The motion also stays Neuralstem's Counter Claims against StemCells Inc....
Speak with other shareholders about: (OTC: HLUN), (NASDAQ: STEM), (NASDAQ: OSIP).
M2 PRESSWIRE-14 May 2007-Stockwire.com: Speak with other shareholders about: (OTC: HLUN), (NASDAQ: STEM), (NASDAQ: OSIP)C1994-2007 M2 COMMUNICATIONS LTD RDATE:14052007 AUSTIN, TX -- Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites...
News Roundup: Companies Of Interest!
M2 PRESSWIRE-14 May 2007-Businessnetwire.us: News Roundup: Companies Of Interest!C1994-2007 M2 COMMUNICATIONS LTD RDATE:14052007 New York, NY - HEALTHeUNIVERSE Inc. (OTC: HLUN); StemCells, Inc. (NASDAQ: STEM); OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) BusinessNetWire is an affiliate of Stock Profiler.US. To receive...
Todays News: Companies Of Interest!
M2 PRESSWIRE-9 May 2007-Businessnetwire.us: Todays News: Companies Of Interest!C1994-2007 M2 COMMUNICATIONS LTD RDATE:09052007 New York, NY - HealthSonix, Inc. (OTC: HSXI); HEALTHeUNIVERSE Inc. (PINKSHEETS: HLUN); Aastrom Biosciences, Inc. (Nasdaq: ASTM); StemCells, Inc. (NASDAQ: STEM) BusinessNetWire is an affiliate...
FEATURED STOCK: Aegis Industries, Inc. (OTCBB: AGIN).
M2 PRESSWIRE-10 April 2007-WallStreetAnalystReport.com: FEATURED STOCK: Aegis Industries, Inc. (OTCBB: AGIN)C1994-2007 M2 COMMUNICATIONS LTD RDATE:10042007 Stocks To Watch: Aegis Industries, Inc. (OTCBB: AGIN), NewMarket Technology, Inc. (OTCBB: NMKT), Novavax, Inc. (Nasdaq: NVAX), WGL Entertainment Holdings, Inc. (OTC BB:WGLT), StemCells Inc....
Techvest 7th Annual Healthcare Conference Presenter Profiles
NEW YORK -- Techvest 7th Annual Healthcare Conference takes place 07 - 09 Nov. at the New York Palace Hotel in New York City. For in-depth information about the event visit http://www.rodmanandrenshaw.com/index.htm. Below are profiles from Techvest 7th Annual Healthcare Conference presenters. News releases, web cast advisories, and photos...
StemCells, Inc. receives FDA clearance to initiate Phase I clinical trial of neural stem cells and BioCryst to release 3Q 2005 financial results on October 26, 2005.
M2 PRESSWIRE-21 October 2005-US Financial Network: StemCells, Inc. receives FDA clearance to initiate Phase I clinical trial of neural stem cells and BioCryst to release 3Q 2005 financial results on October 26, 2005C1994-2005 M2 COMMUNICATIONS LTD RDATE:21102005 City of Industry, CA...
StemCells, Inc. Moves to Nasdaq National Market
PALO ALTO, Calif. -- StemCells, Inc. (NASDAQ: STEM) today announced that the Nasdaq Stock Market has approved its application to transfer the listing of its common stock to the National Market from the Capital Market. The Company's stock will continue to trade under its current symbol, STEM. "Our move...
U.S. BioDefense receives first stem cell line and extends agreement with University of British Columbia & StemCells, Inc. announces filing of IND amendment for treatment for Batten disease.
M2 PRESSWIRE-20 September 2005-US Financial Network: U.S. BioDefense receives first stem cell line and extends agreement with University of British Columbia & StemCells, Inc. announces filing of IND amendment for treatment for Batten diseaseC1994-2005 M2 COMMUNICATIONS LTD RDATE:20092005 City of...
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes

